Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.53 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7504889 | 0.93 | CYP2D6 (0.52) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL1997960 | 0.93 | NPFFR1 (0.58) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL23120819 | 0.85 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL22961966 | 0.85 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL28249793 | 0.85 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL1770778 | 0.84 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL4795708 | 0.84 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL4295050 | 0.84 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL1036462 | 0.84 | NPFFR1 (0.52) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL23268874 | 0.84 | NPFFR1 (0.52) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2678329-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
| EP-2010488-A2 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1987020-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117559-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007093364-A1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | NPFFR1 4140/4885NPFFR2 4313/4885CYP2D6 558/4885 |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | NPFFR1 2240/4885NPFFR2 3346/4885CYP2D6 456/4885 |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | DPYD, TYMS, TYMP | NPFFR1 4295/4885NPFFR2 4451/4885CYP2D6 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.